Nanette Santoro

Nov 14, 2024 | healio.com | Erin T. Welsh |Richard Smith |Nanette Santoro

Nanette Santoro, MD If you are looking to see if hormone therapy makes a difference in mortality for women, this is not a preferred study design. It is a retrospective cohort study, which means users and nonusers of HT may differ in meaningful ways that are related to mortality, thereby attributing a benefit to hormones that might not exist. Table 1 in the study shows that almost all of the characteristics of the two populations differ.

May 16, 2024 | thelancet.com | Genevieve Scott Neal-Perry |Nanette Santoro |Antonio Caño |Rossella E Nappi

We read with interest the Correspondence from Jonathan Douxfils and colleagues regarding an increased risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant. 1Douxfils J Beaudart C Dogné J-M Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant. However, important considerations warrant clarification. The numeric imbalance identified in SKYLIGHT 4 (see appendix 4 in the full-length study paper)2Neal-Perry G Cano A Lederman S et al.

Mar 20, 2024 | healio.com | Richard Smith |Nanette Santoro

You've successfully added Menopause to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Women reported significantly reduced menopausal vasomotor symptom frequency with once-daily oral elinzanetant.

Nov 16, 2023 | consultant360.com | Nanette Santoro

In this video, Nanette Santoro, MD, discusses the efficacy of nonhormonal treatment for patients with vasomotor symptoms (VMS), also called hot flashes or night sweats, in subgroups of patients considered unsuitable for or unwilling to take hormone therapy based on hormonal therapy history, the efficacy of the nonhormonal treatment for patients with VMS in menopause according to time of day, and pooled safety data over 52 weeks of the nonhormonal treatment for patients with VMS in menopause.

Sep 29, 2023 | healio.com | Jill Rollet |Nanette Santoro |Michael Monostra

Source/Disclosures Source: Healio Interviews Disclosures: Santoro reports serving on the scientific advisory board for Astellas. Source/Disclosures Source: Healio Interviews Disclosures: Santoro reports serving on the scientific advisory board for Astellas. You've successfully added Women's Health: Menopause to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request.